Cadrenal Therapeutics, Inc. 2023 Form 10-K Summary
Business context and reporting period
Cadrenal Therapeutics is a development-stage biopharmaceutical company incorporated in January 2022. The company is developing tecarfarin, an investigational, oral, reversible vitamin K antagonist intended for chronic anticoagulation in underserved populations, including patients with end-stage kidney disease and atrial fibrillation, left ventricular assist devices, and thrombotic antiphospholipid syndrome.
The filing covers the fiscal year ended December 31, 2023, compared primarily with the period from January 25, 2022, through December 31, 2022. Tecarfarin has FDA orphan drug designation for ESKD and atrial fibrillation and FDA Fast Track designation granted in 2023. It has not been approved for marketing and the company generated no product revenue.
Financial and operating metrics
| Metric | 2023 | Comparable period |
|---|---|---|
| Revenue | $0; the company has not generated operating revenue | $0 |
| General and administrative expense | $3.55 million | $2.31 million |
| Research and development expense | $4.08 million | $0.39 million |
| Total operating expenses | $7.63 million | $2.70 million |
| Operating loss | $7.63 million | $2.70 million |
| Net loss | $8.36 million | $6.71 million |
| Net loss per share | $0.62 basic and diluted | $0.85 basic and diluted |
| Cash used in operating activities | $3.53 million | $1.20 million |
| Cash and cash equivalents at period-end | $8.40 million | $0.03 million |
| Debt at period-end | $0 | $0.60 million, net |
Gross margin and operating margin are not meaningful because the company has no product sales. The 2023 net loss included $4.68 million of non-cash expenses, including $3.0 million of stock issued to settle an asset-purchase obligation, $0.74 million of debt-extinguishment expense, equity-based compensation, and other non-cash items.
Net cash provided by financing activities was $11.90 million, consisting principally of approximately $5.41 million of net IPO proceeds and $6.49 million of net proceeds from the July 2023 private placement. The company reported approximately $6.9 million of cash as of March 8, 2024, and stated that this amount should fund operations for at least the next twelve months, but not the full planned Phase 3 program and NDA submission.
Material changes versus the prior comparable period
- Operating expenses increased by approximately $4.93 million, or 183%, primarily because of higher research and development activity, public-company costs, personnel, insurance, consulting, and professional fees.
- Research and development expense increased by approximately $3.69 million, largely due to the issuance of 600,000 shares valued at $3.0 million to HESP LLC under the tecarfarin asset purchase agreement.
- Cash increased from $32,586 to $8.40 million following the IPO, July private placement, and warrant exercise proceeds.
- All convertible notes, related accrued interest, derivative liabilities, and the November 2022 promissory notes were settled in connection with the January 2023 IPO. The company ended 2023 with no debt.
- Shares outstanding increased from 8.19 million at December 31, 2022 to 13.02 million at December 31, 2023, excluding subsequent warrant exercises. As of March 8, 2024, 16.01 million shares were outstanding.
- The July 2023 financing included 1.30 million common shares, 2.99 million pre-funded warrants, and 4.29 million common warrants. All pre-funded warrants were exercised by February 26, 2024, for approximately $298 of proceeds and 2.99 million common shares.
Clinical program, outlook, risks and unusual items
- Management plans to initiate the pivotal ACTOR AF Phase 3 trial in 2025, subject to additional financing and FDA acceptance of the proposed protocol. The planned study is expected to enroll approximately 540 subjects, with 492 evaluable subjects, and assess time to first major adverse cardiovascular event.
- A two-year animal carcinogenicity study readout is expected in the first half of 2025. The company expects to conduct any additional studies required by the FDA.
- Prior tecarfarin studies involved more than 1,000 individuals. In the EMBRACE-AC Phase 2/3 trial, tecarfarin did not achieve statistical superiority to warfarin on the primary TTR endpoint; interpolated TTR was 72.3% for tecarfarin versus 71.5% for warfarin. A post-hoc analysis excluding periods off study drug showed TTR of 68.8% versus 66.4%, respectively.
- In EMBRACE-AC, major bleeding occurred in 1.6% of blinded tecarfarin subjects. The filing reports no thrombotic events among tecarfarin-treated subjects, but these historical results may not predict the planned Phase 3 outcome.
- The company requires substantial additional capital to initiate and complete Phase 3 development and submit an NDA. It has no committed financing facility and may seek equity, debt, licensing, or partnering transactions, which could cause dilution or require the company to relinquish rights.
- Two issued U.S. patents covering tecarfarin were reported to expire on April 8, 2024, absent applicable extensions; corresponding foreign patents expire in 2025. The company’s long-term protection therefore depends on patent-term extensions, additional filings, and regulatory or market exclusivity.
- Cadrenal relies on third parties for clinical trials, manufacturing, and supply. It has no long-term supply or commercialization agreements and has limited internal commercial infrastructure.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and no cybersecurity incidents through the filing date. Management concluded that disclosure controls and internal control over financial reporting were effective; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company and smaller-reporting-company status.
- Nasdaq notified the company of a minimum-bid-price deficiency. Nasdaq granted an extension through September 3, 2024 to regain compliance with the $1.00 bid-price requirement, subject to applicable Nasdaq procedures.
Most important facts for investors to verify
- Whether additional financing or a strategic partnership is secured in time to fund the ACTOR AF Phase 3 trial.
- Whether the FDA accepts the proposed Phase 3 protocol and whether the trial ultimately demonstrates a clinically and statistically meaningful benefit.
- Current cash burn, remaining cash runway, and the expected total cost of Phase 3 development and NDA submission.
- The status of U.S. patent-term extensions, other patent applications, orphan-drug exclusivity, and potential competing anticoagulants.
- Potential dilution from the 7.66 million warrants outstanding at December 31, 2023, stock options, the 2022 equity plan, and future capital raises.
- Compliance with Nasdaq’s minimum-bid-price requirement and any subsequent listing or reverse-split actions.
- Whether historical clinical data generated by prior owners and third parties are sufficient for FDA use and can be replicated in the company’s planned trial.
- The filing’s stated market opportunity estimate of more than $2 billion annually, which is dependent on approval, pricing, reimbursement, and successful commercialization and is not a current revenue forecast.